Connect with us

Science

CBN discovery could lead to new treatments for Alzheimer’s, say researchers

A new study suggests CBN has the potential for treating age-related neurodegenerative diseases.

Published

on

CBN shows potential for Alzeimer's

More findings on the cannabinoid CBN could lead to the development of new treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, say researchers.

A new study by scientists at the Salk Institute in California, suggests CBN has the potential for treating age-related neurodegenerative diseases, like Alzheimer’s.

Derived from the cannabis plant, CBN is similar to THC, but is not psychoactive and is less heavily regulated by bodies such as the FDA. 

Previous research by senior author Pamela Maher, a research professor and head of Salk’s Cellular Neurobiology Laboratory, found that CBN had neuroprotective properties, but it wasn’t clear how it worked. 

Now, these new findings, published in the journal Free Radical Biology and Medicine, explain the mechanism through which CBN protects brain cells from damage and death.

“We’ve found that cannabinol protects neurons from oxidative stress and cell death, two of the major contributors to Alzheimer’s,” says Maher.

“This discovery could one day lead to the development of new therapeutics for treating this disease and other neurodegenerative disorders, like Parkinson’s disease.”

Maher’s team looked at the process of oxytosis, which is thought to occur in the ageing brain, and which growing evidence suggests may be a cause of Alzheimer’s disease. 

In the study, the scientists treated nerve cells with CBN, and then introduced an agent to stimulate oxidative damage.

They found that the CBN worked by protecting mitochondria, the cell’s powerhouses, within the neurons. In damaged cells, oxidation causes the mitochondria to curl up like donuts—a change that’s also been seen in ageing cells taken from the brains of people with Alzheimer’s disease. 

However, treating cells with CBN prevented the mitochondria from curling up and kept them functioning well.  

To confirm the interaction between CBN and mitochondria, researchers then replicated the experiment in nerve cells that had the mitochondria removed. In these cells, CBN no longer demonstrated its protective effect.

“We were able to directly show that maintenance of mitochondrial function was specifically required for the protective effects of the compound,” Maher said.

Potential for other diseases

In another key finding, researchers showed that CBN did not activate cannabinoid receptors, which are required for cannabinoids to produce a psychoactive response. Thus, CBN therapeutics would work without causing the individual to become “high.”

First author Zhibin Liang, a postdoctoral fellow in the Maher lab, said: “CBN is not a controlled substance like THC, the psychotropic compound in cannabis, and evidence has shown that CBN is safe in animals and humans. And because CBN works independently of cannabinoid receptors, CBN could also work in a wide variety of cells with ample therapeutic potential.”

In addition to Alzheimer’s, the findings have implications for other neurodegenerative diseases, such as Parkinson’s, which is also linked to glutathione loss.

“Mitochondrial dysfunction is implicated in changes in various tissues, not just in the brain and ageing, so the fact that this compound is able to maintain mitochondrial function suggests it could have more benefits beyond the context of Alzheimer’s disease,” Maher said.

She added that the study shows the need for further research into CBN and other lesser-studied cannabinoids.

[activecampaign form=33]

Estimated reading time: 3 minutes

Home » Science » CBN discovery could lead to new treatments for Alzheimer’s, say researchers

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.